R.W. Blamey
- Cancer Research top 0.5%
- Breast Cancer Treatment Studies 57
- Oncology top 0.5%
- HER2/EGFR in Cancer Research 21
- Global Cancer Incidence and Screening 14
- Cancer Treatment and Pharmacology 10
- Cancer Risks and Factors 9
-
- Breast Lesions and Carcinomas 25
- Genetics top 1%
- Estrogen and related hormone effects 31
- Dermatology top 1%
- Cancer and Skin Lesions 11
- Co-authors
- Ian O. EllisC.W. ElstonLesley FallowfieldS. K. Al-GhazalRobert I. NicholsonJ.F.R. RobertsonK. GriffithsJ. L. Haybittle
- Partner nations
- United KingdomAustraliaGreece
In The Last Decade
R.W. Blamey
127 papers receiving 4.9k citations
Hit Papers
Peers
Comparison fields: 5 of 126
- Cancer Research 2.3k
- Oncology 2.7k
- Pathology and Forensic Medicine 1.2k
- Genetics 1.7k
- Dermatology 328
Countries citing papers authored by R.W. Blamey
This map shows the geographic impact of R.W. Blamey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R.W. Blamey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R.W. Blamey more than expected).
Fields of papers citing papers by R.W. Blamey
This network shows the impact of papers produced by R.W. Blamey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R.W. Blamey. The network helps show where R.W. Blamey may publish in the future.
Co-authorship network
The 25 scholars most cited alongside R.W. Blamey, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2009 | 66 | |
| 2 | 2005 | 4 | |
| 3 | 2003 | 34 | |
| 4 | 2000 | 14 | |
| 5 | C-erbB2 expression predicts response to preoperative chemotherapy for locally advanced breast cancer. | 1999 | 25 |
| 6 | 1997 | 3 | |
| 7 | 1997 | 28 | |
| 8 | Tissue factor A new independent prognostic marker in breast cancer | 1996 | 2 |
| 9 | 1995 | 130 | |
| 10 | Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression. | 1994 | 102 |
| 11 | 1993 | 22 | |
| 12 | Surgery versus tamoxifen in selected elderly patients with operable breast cancer Early results of a randomised trial | 1992 | 1 |
| 13 | An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. | 1991 | 89 |
| 14 | 1990 | 48 | |
| 15 | 1988 | 113 | |
| 16 | 1988 | 7 | |
| 17 | 1986 | 7 | |
| 18 | 1981 | 4 | |
| 19 | 1980 | 94 | |
| 20 | Estrogen receptor assay in primary breast cancer and early recurrence of the disease. | 1978 | 114 |
About R.W. Blamey
R.W. Blamey is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine, having authored 130 papers that have together received 5.2k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (57 papers), Estrogen and related hormone effects (31 papers), Breast Lesions and Carcinomas (25 papers), HER2/EGFR in Cancer Research (21 papers), Global Cancer Incidence and Screening (14 papers), Cancer and Skin Lesions (11 papers), Cancer Treatment and Pharmacology (10 papers) and Cancer Risks and Factors (9 papers). The work is most often cited by research in Cancer Research (2.3k citations), Oncology (2.7k citations) and Pathology and Forensic Medicine (1.2k citations). R.W. Blamey has collaborated with scholars based in United Kingdom, Australia and Greece. Frequent co-authors include Ian O. Ellis, C.W. Elston, Lesley Fallowfield, S. K. Al-Ghazal, C.W. Elston, Robert I. Nicholson, J.F.R. Robertson, J.F.R. Robertson, K. Griffiths and J. L. Haybittle. Their work appears in journals such as The Lancet, Journal of Clinical Oncology and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.